The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
The companies aim to expand treatment options for millions living with metabolic disorders
Subscribe To Our Newsletter & Stay Updated
